---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-029903"
form_type: "8-K"
ticker: "OTLC"
cik: "0000908259"
company_name: "Oncotelic Therapeutics, Inc."
filed_at: "2023-08-23T23:59:59+00:00"
generated_at: "2026-06-11T05:15:40.034237+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Oncotelic JV Sapu starts registrational Phase 2b/3 trial of OT-101 in pancreatic cancer

## Summary
- Sapu Bioscience (Oncotelic 45% JV partner) signed master services agreement with Cromos Pharma for OT-101 registrational trial.
- Trial: Phase 2b/3 of TGF-β2 antisense OT-101 + FOLFIRINOX vs FOLFIRINOX alone in advanced/metastatic pancreatic cancer.
- Multinational trial targeting up to 500 patients across USA, EU, and China.
- Oncotelic CEO states TGFβ2 suppression may more than double survival in pancreatic cancer.

## SEC filing metadata
- accession: 0001493152-23-029903
- form_type: 8-K
- ticker: OTLC
- cik: 0000908259
- company_name: Oncotelic Therapeutics, Inc.
- filed_at: 2023-08-23T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/908259/000149315223029903/0001493152-23-029903-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/908259/000149315223029903/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-029903
- JSON: https://secwatch.observer/filing/0001493152-23-029903.json
- Plain text: https://secwatch.observer/filing/0001493152-23-029903.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.